Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19263925 | 1.00 | TDP1 (0.43) | TDP1MAPK1HSD17B10LMNAL3MBTL1 | |
| SCHEMBL10866121 | 0.86 | LMNA (0.43) | TDP1MAPK1HSD17B10LMNAL3MBTL1 | |
| SCHEMBL25382424 | 0.85 | TSHR (0.38) | TDP1LMNAL3MBTL1TSHRKDM4E | |
| SCHEMBL21136347 | 0.83 | LMNA (0.36) | TDP1MAPK1LMNAL3MBTL1TSHR | |
| SCHEMBL6249346 | 0.82 | TDP1 (0.38) | TDP1MAPK1HSD17B10LMNA | |
| SCHEMBL17917003 | 0.81 | TDP1 (0.33) | TDP1LMNAL3MBTL1 | |
| SCHEMBL17898232 | 0.81 | TDP1 (0.36) | TDP1MAPK1HSD17B10 | |
| SCHEMBL1959442 | 0.80 | TDP1 (0.43) | TDP1MAPK1HSD17B10LMNATSHR | |
| SCHEMBL15780471 | 0.80 | TDP1 (0.43) | TDP1MAPK1HSD17B10LMNATSHR | |
| Propylene Glycol SCHEMBL5833472 | 0.80 | TDP1 (0.50) | TDP1MAPK1HSD17B10LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170283450-A1 | TRITERPENE SAPONINS, METHODS OF SYNTHESIS AND USES THEREOF | MEMORIAL SLOAN-KETTERING INST FOR CANCER RES (US) | 2017-10-05 | — | — | US | disclosed |
| US-9718850-B2 | Triterpene saponins, methods of synthesis and uses thereof | MEMORIAL SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2017-08-01 | — | — | US | disclosed |
| US-20110300177-A1 | TRITERPENE SAPONINS, METHODS OF SYNTHESIS, AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110300177-A1 | TRITERPENE SAPONINS, METHODS OF SYNTHESIS, AND USES THEREOF | LSS, CYP51A1, TLR7 | TDP1 1614/4885MAPK1 2601/4885HSD17B10 1727/4885 |
| US-20170283450-A1 | TRITERPENE SAPONINS, METHODS OF SYNTHESIS AND USES THEREOF | LSS, CYP51A1, TLR7 | TDP1 1513/4885MAPK1 2595/4885HSD17B10 1813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.